Carmen Priolo, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphangioleiomyomatosis | 8 | 2022 | 206 | 1.730 |
Why?
|
| Tuberous Sclerosis | 8 | 2022 | 1039 | 1.200 |
Why?
|
| gamma-Glutamyltransferase | 2 | 2022 | 142 | 0.640 |
Why?
|
| Angiomyolipoma | 1 | 2020 | 189 | 0.610 |
Why?
|
| Phosphatidylcholines | 1 | 2018 | 403 | 0.540 |
Why?
|
| Tumor Suppressor Proteins | 7 | 2017 | 2795 | 0.510 |
Why?
|
| Lysophosphatidylcholines | 1 | 2015 | 77 | 0.490 |
Why?
|
| Kidney Neoplasms | 4 | 2022 | 4282 | 0.470 |
Why?
|
| Imidazoles | 1 | 2020 | 1169 | 0.450 |
Why?
|
| Oligopeptides | 1 | 2018 | 1195 | 0.410 |
Why?
|
| Multiprotein Complexes | 6 | 2017 | 1107 | 0.400 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2013 | 133 | 0.400 |
Why?
|
| Prostatic Neoplasms | 10 | 2014 | 11094 | 0.390 |
Why?
|
| Mitochondria | 4 | 2021 | 3672 | 0.370 |
Why?
|
| TOR Serine-Threonine Kinases | 8 | 2019 | 2057 | 0.370 |
Why?
|
| Lipid Metabolism | 2 | 2018 | 1893 | 0.350 |
Why?
|
| Lipogenesis | 3 | 2021 | 217 | 0.330 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2014 | 998 | 0.320 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 3594 | 0.310 |
Why?
|
| Pyrimidines | 1 | 2020 | 3050 | 0.290 |
Why?
|
| Sirolimus | 5 | 2022 | 1541 | 0.280 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2022 | 3186 | 0.280 |
Why?
|
| Glucose | 3 | 2021 | 4335 | 0.270 |
Why?
|
| Carbon-Nitrogen Lyases | 1 | 2006 | 8 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2455 | 0.250 |
Why?
|
| Energy Metabolism | 4 | 2021 | 2894 | 0.250 |
Why?
|
| Glutathione | 3 | 2022 | 589 | 0.220 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2019 | 678 | 0.220 |
Why?
|
| Endopeptidases | 1 | 2006 | 760 | 0.200 |
Why?
|
| Thyroid Neoplasms | 5 | 2021 | 2354 | 0.200 |
Why?
|
| Positron-Emission Tomography | 2 | 2018 | 6545 | 0.200 |
Why?
|
| Signal Transduction | 8 | 2020 | 23605 | 0.200 |
Why?
|
| Amino Acid Transport System y+ | 1 | 2022 | 41 | 0.200 |
Why?
|
| Cysteine Proteases | 1 | 2022 | 13 | 0.200 |
Why?
|
| Cystine | 1 | 2022 | 96 | 0.200 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2014 | 8612 | 0.190 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2021 | 2054 | 0.190 |
Why?
|
| Mice, Inbred NOD | 2 | 2020 | 1837 | 0.190 |
Why?
|
| Apoptosis | 5 | 2020 | 9508 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2020 | 2838 | 0.180 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2021 | 72 | 0.180 |
Why?
|
| beta Catenin | 2 | 2019 | 1047 | 0.160 |
Why?
|
| Fluoroacetates | 1 | 2018 | 13 | 0.160 |
Why?
|
| Polyamines | 1 | 2019 | 132 | 0.160 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2014 | 594 | 0.150 |
Why?
|
| Mice | 16 | 2022 | 81839 | 0.150 |
Why?
|
| Sphingosine | 1 | 2020 | 306 | 0.150 |
Why?
|
| Lysophospholipids | 1 | 2020 | 335 | 0.140 |
Why?
|
| Lymphangiogenesis | 1 | 2019 | 171 | 0.140 |
Why?
|
| Precancerous Conditions | 1 | 2024 | 975 | 0.140 |
Why?
|
| Cell Proliferation | 7 | 2020 | 10433 | 0.140 |
Why?
|
| Patient Selection | 1 | 2009 | 4249 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 6102 | 0.130 |
Why?
|
| Animals | 19 | 2022 | 168800 | 0.130 |
Why?
|
| Choline | 1 | 2018 | 511 | 0.130 |
Why?
|
| Naphthyridines | 2 | 2015 | 184 | 0.130 |
Why?
|
| Mice, Transgenic | 4 | 2018 | 9540 | 0.130 |
Why?
|
| Cell Line, Tumor | 10 | 2021 | 17071 | 0.130 |
Why?
|
| Sterol Regulatory Element Binding Proteins | 1 | 2015 | 25 | 0.130 |
Why?
|
| Metabolomics | 3 | 2021 | 1667 | 0.120 |
Why?
|
| Phospholipases A2 | 1 | 2015 | 197 | 0.120 |
Why?
|
| Benzophenanthridines | 1 | 2014 | 26 | 0.120 |
Why?
|
| Mice, SCID | 4 | 2017 | 2626 | 0.120 |
Why?
|
| Receptors, LDL | 1 | 2017 | 492 | 0.120 |
Why?
|
| Oxygen Consumption | 2 | 2018 | 1872 | 0.110 |
Why?
|
| 6-Aminonicotinamide | 1 | 2013 | 8 | 0.110 |
Why?
|
| Hemangiopericytoma | 1 | 2014 | 71 | 0.110 |
Why?
|
| Mice, Knockout | 3 | 2020 | 14456 | 0.110 |
Why?
|
| Enzyme Activators | 1 | 2014 | 56 | 0.110 |
Why?
|
| Immunohistochemistry | 7 | 2018 | 11035 | 0.110 |
Why?
|
| Metabolome | 1 | 2021 | 1005 | 0.110 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2013 | 125 | 0.110 |
Why?
|
| Lipopolysaccharides | 1 | 2021 | 2213 | 0.110 |
Why?
|
| Leukocytes | 1 | 2021 | 2030 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 8038 | 0.100 |
Why?
|
| Prostaglandins | 1 | 2014 | 396 | 0.100 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 13635 | 0.100 |
Why?
|
| Indoles | 3 | 2019 | 1833 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 1890 | 0.100 |
Why?
|
| Mice, Nude | 3 | 2022 | 3610 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 715 | 0.100 |
Why?
|
| Lysosomes | 1 | 2017 | 932 | 0.090 |
Why?
|
| Pericytes | 1 | 2014 | 299 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2014 | 1167 | 0.090 |
Why?
|
| Taxoids | 1 | 2014 | 665 | 0.090 |
Why?
|
| RNA, Small Interfering | 5 | 2019 | 3424 | 0.090 |
Why?
|
| Endothelial Cells | 2 | 2021 | 3586 | 0.090 |
Why?
|
| Mass Spectrometry | 2 | 2015 | 2195 | 0.090 |
Why?
|
| Rats | 2 | 2018 | 23717 | 0.090 |
Why?
|
| Mutation | 5 | 2021 | 30209 | 0.090 |
Why?
|
| Humans | 36 | 2024 | 766117 | 0.090 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 798 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2017 | 1852 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2021 | 4342 | 0.080 |
Why?
|
| Oxidative Stress | 2 | 2018 | 3140 | 0.080 |
Why?
|
| Autophagy | 2 | 2014 | 1349 | 0.080 |
Why?
|
| Estradiol | 2 | 2014 | 1947 | 0.080 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2009 | 167 | 0.080 |
Why?
|
| Thrombospondin 1 | 1 | 2010 | 256 | 0.080 |
Why?
|
| Wnt1 Protein | 1 | 2008 | 120 | 0.080 |
Why?
|
| Lung Neoplasms | 3 | 2024 | 13483 | 0.070 |
Why?
|
| Estrogen Receptor beta | 1 | 2009 | 171 | 0.070 |
Why?
|
| Cell Movement | 1 | 2020 | 5196 | 0.070 |
Why?
|
| Cholesterol | 1 | 2017 | 2902 | 0.070 |
Why?
|
| Palmitic Acid | 1 | 2008 | 147 | 0.070 |
Why?
|
| Male | 18 | 2021 | 363935 | 0.070 |
Why?
|
| Cytoplasm | 2 | 2009 | 1498 | 0.070 |
Why?
|
| Sulfonamides | 2 | 2014 | 1980 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2010 | 2510 | 0.070 |
Why?
|
| Carrier Proteins | 2 | 2017 | 4910 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 3692 | 0.070 |
Why?
|
| Colony-Forming Units Assay | 1 | 2006 | 351 | 0.070 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 2010 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2009 | 707 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 2029 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 5388 | 0.060 |
Why?
|
| Hyperhomocysteinemia | 1 | 2006 | 117 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 620 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2009 | 711 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 3604 | 0.060 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2006 | 276 | 0.060 |
Why?
|
| Immunoblotting | 3 | 2014 | 1644 | 0.060 |
Why?
|
| Female | 12 | 2022 | 396233 | 0.060 |
Why?
|
| Hypoparathyroidism | 1 | 2006 | 136 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 3247 | 0.060 |
Why?
|
| DiGeorge Syndrome | 1 | 2006 | 187 | 0.060 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2006 | 165 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 2046 | 0.060 |
Why?
|
| Gene Silencing | 2 | 2009 | 1504 | 0.050 |
Why?
|
| RNA, Neoplasm | 1 | 2006 | 745 | 0.050 |
Why?
|
| Cell Death | 2 | 2022 | 1676 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 18321 | 0.050 |
Why?
|
| Oncogenes | 1 | 2009 | 1232 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2006 | 455 | 0.050 |
Why?
|
| Galectin 3 | 1 | 2005 | 238 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2009 | 1138 | 0.050 |
Why?
|
| Glutathione Disulfide | 1 | 2022 | 32 | 0.050 |
Why?
|
| Receptors, Angiotensin | 1 | 2022 | 141 | 0.050 |
Why?
|
| Transfection | 2 | 2009 | 5739 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 8924 | 0.050 |
Why?
|
| Ubiquitin | 1 | 2006 | 840 | 0.050 |
Why?
|
| Inflammation | 1 | 2021 | 10860 | 0.050 |
Why?
|
| Leukocyte Rolling | 1 | 2021 | 69 | 0.050 |
Why?
|
| Disease Progression | 2 | 2024 | 13616 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2010 | 2463 | 0.040 |
Why?
|
| Peptide Hydrolases | 1 | 2022 | 608 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 502 | 0.040 |
Why?
|
| Maleimides | 1 | 2019 | 112 | 0.040 |
Why?
|
| Cell Line | 3 | 2019 | 15546 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2017 | 2879 | 0.040 |
Why?
|
| RNA Interference | 3 | 2013 | 2828 | 0.040 |
Why?
|
| Carcinoma | 1 | 2009 | 2313 | 0.040 |
Why?
|
| Biological Transport | 1 | 2022 | 2080 | 0.040 |
Why?
|
| Tissue Array Analysis | 2 | 2009 | 544 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 2 | 2022 | 2824 | 0.040 |
Why?
|
| Protein Stability | 1 | 2019 | 576 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2021 | 1336 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2017 | 61 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2013 | 3787 | 0.030 |
Why?
|
| Mammals | 1 | 2022 | 1126 | 0.030 |
Why?
|
| Glycolysis | 1 | 2021 | 837 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 6493 | 0.030 |
Why?
|
| Reactive Oxygen Species | 2 | 2014 | 2144 | 0.030 |
Why?
|
| Phenotype | 3 | 2021 | 16716 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 2221 | 0.030 |
Why?
|
| Lymphatic Vessels | 1 | 2019 | 356 | 0.030 |
Why?
|
| Microvessels | 1 | 2019 | 590 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 602 | 0.030 |
Why?
|
| Adenoma | 1 | 2005 | 2155 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2010 | 9527 | 0.030 |
Why?
|
| Aged | 6 | 2019 | 171219 | 0.030 |
Why?
|
| Mice, Inbred A | 1 | 2013 | 244 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2021 | 1756 | 0.030 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2013 | 53 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2006 | 3684 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 11859 | 0.030 |
Why?
|
| Kinetics | 1 | 2021 | 6273 | 0.030 |
Why?
|
| Teratogens | 1 | 2013 | 120 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2021 | 1805 | 0.030 |
Why?
|
| Caspase 1 | 1 | 2013 | 227 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 2469 | 0.030 |
Why?
|
| Valine | 1 | 2014 | 410 | 0.030 |
Why?
|
| Breath Tests | 1 | 2014 | 297 | 0.030 |
Why?
|
| Chloroquine | 1 | 2013 | 276 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2024 | 3955 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2014 | 364 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2014 | 895 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2019 | 1651 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 6363 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2014 | 595 | 0.020 |
Why?
|
| Lipoxins | 1 | 2014 | 419 | 0.020 |
Why?
|
| Enzyme Inhibitors | 2 | 2013 | 3722 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 5695 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2021 | 11906 | 0.020 |
Why?
|
| Hydroxychloroquine | 1 | 2013 | 429 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 22341 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1602 | 0.020 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2009 | 186 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2009 | 310 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2014 | 1181 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2009 | 5881 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2013 | 1068 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2009 | 314 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 1150 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2019 | 8292 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 1967 | 0.020 |
Why?
|
| Response Elements | 1 | 2009 | 307 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2008 | 858 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2009 | 465 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2017 | 18967 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2009 | 656 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2014 | 2927 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 4853 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 548 | 0.020 |
Why?
|
| Homeostasis | 1 | 2017 | 3338 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4565 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 5336 | 0.020 |
Why?
|
| Survival Rate | 1 | 2019 | 12827 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 6208 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2013 | 2495 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2009 | 1213 | 0.010 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2009 | 632 | 0.010 |
Why?
|
| DNA Primers | 1 | 2008 | 2824 | 0.010 |
Why?
|
| Telomerase | 1 | 2009 | 749 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15403 | 0.010 |
Why?
|
| Cohort Studies | 2 | 2019 | 41684 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2014 | 9378 | 0.010 |
Why?
|
| Dietary Fats | 1 | 2010 | 2003 | 0.010 |
Why?
|
| Aspirin | 1 | 2014 | 3135 | 0.010 |
Why?
|
| Prostatic Hyperplasia | 1 | 2006 | 514 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2009 | 5020 | 0.010 |
Why?
|
| Thyroid Diseases | 1 | 2005 | 385 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2005 | 2271 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 2390 | 0.010 |
Why?
|
| Middle Aged | 5 | 2019 | 223083 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2005 | 1072 | 0.010 |
Why?
|
| Lung | 1 | 2019 | 10063 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2009 | 2864 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2009 | 4133 | 0.010 |
Why?
|
| Genotype | 1 | 2014 | 13028 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 18076 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2017 | 22228 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 2005 | 1168 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 3501 | 0.010 |
Why?
|
| Prostatectomy | 1 | 2006 | 1786 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 5784 | 0.010 |
Why?
|
| Prostate | 1 | 2006 | 1758 | 0.010 |
Why?
|
| Base Sequence | 1 | 2008 | 12405 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3796 | 0.010 |
Why?
|
| Protein Binding | 1 | 2009 | 9301 | 0.010 |
Why?
|
| Prognosis | 2 | 2009 | 29912 | 0.010 |
Why?
|
| Gene Expression | 1 | 2009 | 7582 | 0.010 |
Why?
|
| United States | 1 | 2024 | 72920 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 39243 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2019 | 54812 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 59515 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 11200 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2006 | 11642 | 0.000 |
Why?
|
| Adult | 3 | 2009 | 223139 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2014 | 65219 | 0.000 |
Why?
|
| Obesity | 1 | 2010 | 13085 | 0.000 |
Why?
|